Avenue Therapeutics' AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress
TipRanksApr 3 07:05 ET
Buy Rating Affirmed for Avenue Therapeutics Amid Strong Prospects for IV Tramadol and Strategic Growth Potential
TipRanksFeb 1 07:37 ET
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
TipRanksJan 3 12:20 ET
Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
BenzingaDec 11, 2023 09:43 ET
Avenue Therapeutics Analyst Ratings
BenzingaDec 11, 2023 09:38 ET
Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32
BenzingaApr 3, 2023 13:32 ET
Analysts Are Bullish on Top Healthcare Stocks: Avenue Therapeutics (ATXI), Eli Lilly & Co (LLY)
TipRanksOct 11, 2022 05:05 ET
No Data
No Data